Blue Earth Therapeutics Announces Participation in Upcoming B Riley Securities Radiopharma Investor Conference finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced that it will be presenting at the upcoming B. Riley Securities' Radiopharma Investor.
First reported clinical results from independent clinical experience by University of Augsburg demonstrated encouraging preliminary data for 177Lu-rhPSMA-10.1
– First reported clinical results from independent clinical experience by University of Augsburg demonstrated encouraging preliminary data for 177Lu-rhPSMA-10.1 –– 177Lutetium-labeled radiohybrid (rh) Prostate-Specific Membrane Antigen (177Lu-rhPSMA-10.1) is now in clinical development as a highly optimized, next ge.
Blue Earth Diagnostics Highlights Clinical Utility of POSLUMA (Flotufolastat F 18) PET and Post-scan Changes in Management in Patients with Suspected Recurrence of Prostate Cancer at ASCO GU finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.